GNMSF (GNMSF) Stock Price & Analysis
GNMSF (GNMSF) rose 0.00% to USD 274.5 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
GNMSF last closed at USD 274.5; the session ranged USD 282–282 on volume of 11 shares. Market capitalization is $16.85B, with a 52-week range of USD 216.31–352 (PNK). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 274.5 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 274.5 |
| Open | USD 282 |
| Day Range | USD 282 – 282 |
| 52-Week Range | USD 216.31 – 352 |
| Volume | 11 shares |
| Market Cap | $16.85B |
| Exchange | PNK |
Technical Analysis (GNMSF)
Nexqual's technical model rates GNMSF "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.63 (neutral) |
| vs SMA50 | Above (USD 263.71) |
| MACD | 3.78 (positive) |
Analyst Ratings (GNMSF)
Wall Street analysts rate GNMSF "None", per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | None |
|---|
Earnings (GNMSF)
| Next Earnings Date | 2026-08-06 |
|---|---|
| Revenue Estimate | $7.23B |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (GNMSF)
| Total Revenue | $3.90B |
|---|---|
| Revenue Growth (YoY) | +25.30% |
| Gross Margin | +93.31% |
| Operating Margin | +25.11% |
| Profit Margin | +21.05% |
| ROE | +14.96% |
| Debt / Equity | 94.18 |
| Current Ratio | 2.18 |
| Total Cash | $1.52B |
| Total Debt | $5.35B |
| Free Cash Flow | $830.37M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (GNMSF)
Nexqual rates GNMSF's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 93%, operating 25% |
| Balance Sheet | Mixed — $1.52B cash vs $5.35B debt |
| Cash Flow | Mixed — FCF $830M, slim 3.5% margin |
| Efficiency | Mixed — ROE 15%, ROA 8.5% |
Ownership (GNMSF)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +40.57% |
| Shares Outstanding | 61.39M |
| Float | 60.64M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (GNMSF)
GNMSF is led by Jan G.J. van de Winkel (age 64), Co-Founder, President & CEO, per Nexqual as of July 25, 2026 at 03:08 UTC.
| Co-Founder, President & CEO | Jan G.J. van de Winkel (age 64) |
|---|---|
| Executive VP & CFO | Anthony Pagano (age 47) |
| Executive VP & Chief Strategy Officer | Martine J. van Vugt (age 54) |
| Senior Director, Head of Development Business Partnership & Strategy and Director | Martin Schultz (age 50) |
| VP, Head of Antibody Research Materials & Director | Mijke Zachariasse (age 52) |
Major Backers & Investors (GNMSF)
Notable institutional backers of GNMSF include HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT., Bernstein Fund Inc-International Strategic Equities Portfolio, Fidelity, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT. | 0.76% |
| Bernstein Fund Inc-International Strategic Equities Portfolio | 0.73% |
| Fidelity | 0.37% |
| Baird Funds Inc-Baird Chautauqua International Growth Fund | 0.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.65% |
| BlackRock | 1.05% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CMXHF | CSL Ltd. | USD 81.96 | ▲ 0% |
| UCBJY | UCB S.A. | USD 139.01 | ▼ 0.04% |
| CSLLY | CSL Ltd. | USD 20 | ▼ 3.85% |
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 17.52 | ▲ 2.88% |
| LZAGF | Lonza Group AG | USD 675.41 | ▲ 2.42% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.